28 October 2015 - Bristol-Myers Squibb Company today announced that the U.S. FDA has approved Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.

For more details, go to: http://news.bms.com/press-release/financial-news/bristol-myers-squibb-receives-approval-us-food-and-drug-administration-